CN106232615B - 肽及其使用方法 - Google Patents

肽及其使用方法 Download PDF

Info

Publication number
CN106232615B
CN106232615B CN201580011074.8A CN201580011074A CN106232615B CN 106232615 B CN106232615 B CN 106232615B CN 201580011074 A CN201580011074 A CN 201580011074A CN 106232615 B CN106232615 B CN 106232615B
Authority
CN
China
Prior art keywords
peptide
protein
peptides
seq
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580011074.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN106232615A (zh
Inventor
M·多克卡尔
T·波拉考斯基
F·特坎普
R·哈特曼
M·帕斯切克
B·哈特裂帛
F·施弗林格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3B Pharmaceuticals GmbH
Original Assignee
3B Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3B Pharmaceuticals GmbH filed Critical 3B Pharmaceuticals GmbH
Publication of CN106232615A publication Critical patent/CN106232615A/zh
Application granted granted Critical
Publication of CN106232615B publication Critical patent/CN106232615B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201580011074.8A 2014-02-28 2015-02-27 肽及其使用方法 Expired - Fee Related CN106232615B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461946103P 2014-02-28 2014-02-28
US61/946,103 2014-02-28
PCT/US2015/018041 WO2015131061A1 (en) 2014-02-28 2015-02-27 Peptides and methods of use

Publications (2)

Publication Number Publication Date
CN106232615A CN106232615A (zh) 2016-12-14
CN106232615B true CN106232615B (zh) 2021-06-01

Family

ID=52633723

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580011074.8A Expired - Fee Related CN106232615B (zh) 2014-02-28 2015-02-27 肽及其使用方法

Country Status (16)

Country Link
US (2) US9447147B2 (enExample)
EP (1) EP3110841B1 (enExample)
JP (1) JP6711761B2 (enExample)
KR (1) KR20160126075A (enExample)
CN (1) CN106232615B (enExample)
AU (1) AU2015222846B2 (enExample)
BR (1) BR112016019484A2 (enExample)
CA (1) CA2939658C (enExample)
EA (1) EA201691749A1 (enExample)
ES (1) ES2873956T3 (enExample)
IL (1) IL247448B (enExample)
MX (1) MX385558B (enExample)
PH (1) PH12016501608B1 (enExample)
SG (2) SG10201807066UA (enExample)
WO (1) WO2015131061A1 (enExample)
ZA (1) ZA201605518B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021268943A1 (en) * 2020-05-05 2022-11-24 Vega Therapeutics, Inc. Protein S antibodies, methods of making and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103025345A (zh) * 2010-03-19 2013-04-03 巴克斯特国际公司 Tfpi抑制剂及使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5321123A (en) * 1991-07-02 1994-06-14 The Scripps Research Institute Protein S polypeptides and anti-peptide antibodies that inhibit protein S binding to C4B binding protein, diagnostic systems and therapeutic methods
SE9604378D0 (sv) * 1996-11-27 1996-11-27 Tac Ab Methods and reagents for determining protein S
JP2005510516A (ja) * 2001-11-09 2005-04-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドおよびプロテインｓ阻害剤を含む薬学的組成物
US8962563B2 (en) 2009-12-21 2015-02-24 Baxter International, Inc. TFPI inhibitors and methods of use
US9073990B2 (en) * 2010-04-05 2015-07-07 Bar-Llan University Protease-activatable pore-forming polypeptides
CN104211799B (zh) * 2013-05-29 2017-12-26 成都渊源生物科技有限公司 人源egf结构域蛋白及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103025345A (zh) * 2010-03-19 2013-04-03 巴克斯特国际公司 Tfpi抑制剂及使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A region of vitamin K-dependent protein S that binds to C4b binding protein (C4BP) identified using bacteriophage peptide display libraries;Linse S et al;《The Journal of Biological Chemistry》;19970606;第272卷(第23期);14658-14665 *
S蛋白及其功能和临床意义;李景吾 等;《国外医学临床生物化学与检验学分册》;19930731;第14卷(第4期);155-157 *

Also Published As

Publication number Publication date
IL247448A0 (en) 2016-11-30
WO2015131061A1 (en) 2015-09-03
US10124033B2 (en) 2018-11-13
CA2939658A1 (en) 2015-09-03
US20150246947A1 (en) 2015-09-03
PH12016501608A1 (en) 2016-10-03
AU2015222846A1 (en) 2016-08-25
EP3110841A1 (en) 2017-01-04
EA201691749A1 (ru) 2016-12-30
CA2939658C (en) 2022-10-04
SG10201807066UA (en) 2018-09-27
JP6711761B2 (ja) 2020-06-17
PH12016501608B1 (en) 2022-07-01
BR112016019484A2 (pt) 2017-10-24
JP2017509602A (ja) 2017-04-06
KR20160126075A (ko) 2016-11-01
AU2015222846B2 (en) 2019-09-19
CN106232615A (zh) 2016-12-14
ZA201605518B (en) 2018-12-19
MX385558B (es) 2025-03-18
US9447147B2 (en) 2016-09-20
IL247448B (en) 2022-09-01
US20170035835A1 (en) 2017-02-09
ES2873956T3 (es) 2021-11-04
SG11201607067TA (en) 2016-10-28
EP3110841B1 (en) 2021-03-31
MX2016011174A (es) 2016-11-15

Similar Documents

Publication Publication Date Title
JP6567577B2 (ja) Ｔｆｐｉインヒビターおよび使用法
CA2793465C (en) Tfpi inhibitors and methods of use
US10800816B2 (en) TFPI inhibitors and methods of use
CN106232615B (zh) 肽及其使用方法
WO2023143559A1 (en) Tfpi binding polypeptides and uses thereof
EA041584B1 (ru) Пептиды, ингибирующие активность белка s, и их применение для лечения нарушения свертывания крови
HK1206282B (en) Tfpi inhibitors and methods of use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210601